Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Buy at Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Up 1.7%

Shares of Takeda Pharmaceutical stock opened at $15.91 on Friday. The stock has a market capitalization of $50.65 billion, a price-to-earnings ratio of 40.81 and a beta of -0.07. Takeda Pharmaceutical has a twelve month low of $12.99 and a twelve month high of $18.90. The company has a current ratio of 1.09, a quick ratio of 0.60 and a debt-to-equity ratio of 0.59. The business’s 50 day simple moving average is $16.20 and its 200-day simple moving average is $16.79.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. Equities research analysts forecast that Takeda Pharmaceutical will post 0.94 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC raised its stake in Takeda Pharmaceutical by 10.5% during the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after acquiring an additional 2,343 shares in the last quarter. Glenmede Trust Co. NA grew its stake in shares of Takeda Pharmaceutical by 9.6% in the first quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock worth $559,000 after purchasing an additional 2,640 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 95.8% in the first quarter. EverSource Wealth Advisors LLC now owns 25,896 shares of the company’s stock worth $480,000 after purchasing an additional 12,669 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after purchasing an additional 60,725 shares during the period. Finally, Quantinno Capital Management LP increased its holdings in shares of Takeda Pharmaceutical by 20.6% during the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.